We only have this paper's title and publication details.
Read it at the sourcePhase II trial assesses ctDNA as a molecular biomarker in patients with gastrointestinal stromal tumor, indicating potential for personalized treatment.
Representativeness of Study Participants
No takes yet. Share an insight, caveat, or question.
Kelly et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: